Literature DB >> 11082767

Secondary ciliary dyskinesia in upper respiratory tract.

B Bertrand1, S Collet, P Eloy, P Rombaux.   

Abstract

The system of mucociliary clearance has the important task to remove from the airways inhaled substances and locally formed secretions. Inborn disorders of the mucociliary transport are due to ciliary dysfunction (Primary Ciliary Dyskinesia) (PCD) or of increased viscosity of the bronchial secretions (Cystic Fibrosis). To differentiate PCD from the ultrastructural abnormalities found during or after injuries such as respiratory infections, the name of Secondary--or acquired--Ciliary Dyskinesia (SCD) was created. In controls, less than 4% of the cilia may show ultrastructural abnormalities. The most frequent of these are the compound cilia and the peripheral microtubular abnormalities. Compound cilia often appear after infection and therefore are thought to arise secondarily. Secondary ultrastructural abnormalities of cilia include also blebs of the axoneme membrane, ciliary disorientation, and absence of axoneme membrane. No increase in ultrastructural ciliary abnormalities has been found in a variety of respiratory disorders: smoking, asthma and allergic rhinitis, chronic rhinitis and sinusitis, chronic bronchitis, cystic fibrosis, and lung carcinoma. But severe modifications of the respiratory epithelium can be seen. Important for the secondary ciliary disorders is their local and reversible character. To distinct from ultrastructural images between primary and secondary ciliary dyskinesia is often uneasy because some of the findings in secondary ciliary dyskinesia obviously mimic those dedicated to primary ciliary dyskinesia.

Entities:  

Mesh:

Year:  2000        PMID: 11082767

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Belg        ISSN: 0001-6497


  8 in total

1.  Ciliary ultrastructural abnormalities in Mycoplasma pneumoniae pneumonia in 22 pediatric patients.

Authors:  Hui Liang; Wujun Jiang; Qing Han; Feng Liu; Deyu Zhao
Journal:  Eur J Pediatr       Date:  2011-10-26       Impact factor: 3.183

2.  Ciliary ultrastructure in patients with chronic rhinosinusitis and primary ciliary dyskinesia.

Authors:  Ricardo Cassiano Demarco; Edwin Tamashiro; Maria Rossato; Maria Dolores Seabra Ferreira; Fabiana Cardoso Pereira Valera; Wilma T Anselmo-Lima
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-05       Impact factor: 2.503

3.  Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.

Authors:  Justin P McCormick; Christopher G Weeks; Nicholas J Rivers; Jacob D Owen; David R Kelly; Steven M Rowe; George M Solomon; Bradford A Woodworth; Do-Yeon Cho
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-20       Impact factor: 3.858

4.  SARS-CoV-2 Infection Dysregulates Cilia and Basal Cell Homeostasis in the Respiratory Epithelium of Hamsters.

Authors:  Tom Schreiner; Lisa Allnoch; Georg Beythien; Katarzyna Marek; Kathrin Becker; Dirk Schaudien; Stephanie Stanelle-Bertram; Berfin Schaumburg; Nancy Mounogou Kouassi; Sebastian Beck; Martin Zickler; Gülsah Gabriel; Wolfgang Baumgärtner; Federico Armando; Malgorzata Ciurkiewicz
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 5.  Primary ciliary dyskinesia: recent advances in pathogenesis, diagnosis and treatment.

Authors:  Hauw Lie; Thomas Ferkol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Diagnosis of primary ciliary dyskinesia.

Authors:  Mary Anne Kowal Olm; Elia Garcia Caldini; Thais Mauad
Journal:  J Bras Pneumol       Date:  2015 May-Jun       Impact factor: 2.624

7.  Assessment of demographics, treatment strategies, and evidence-based medicine use among diabetic and non-diabetic patients with acute coronary syndrome: A cohort study.

Authors:  Bhavik S Shah; Shrikalp S Deshpande
Journal:  J Pharmacol Pharmacother       Date:  2014-04

Review 8.  Airway Epithelial Cell Cilia and Obstructive Lung Disease.

Authors:  Asma Yaghi; Myrna B Dolovich
Journal:  Cells       Date:  2016-11-11       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.